Analysis of epidermal growth factor receptor gene mutations in patients with non-small cell lung cancer in Shiyan, Hubei
10.3760/cma.j.cn115355-20220517-00312
- VernacularTitle:湖北十堰地区非小细胞肺癌患者表皮生长因子受体基因突变情况分析
- Author:
Huimin HUANG
1
;
Zhengpeng ZHU
;
Ying WEI
Author Information
1. 湖北医药学院附属国药东风总医院实验中心，十堰 442008
- Keywords:
Carcinoma, non-small-cell lung;
Receptor, epidermal growth factor;
Mutation rate
- From:
Cancer Research and Clinic
2022;34(12):921-924
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the epidermal growth factor receptor (EGFR) gene mutation status in patients with non-small cell lung cancer (NSCLC) in Shiyan, Hubei and its relationship with the clinicopathological characteristics of patients.Methods:The data of 173 NSCLC patients who were admitted to Affiliated Dongfeng Hospital of Hubei University of Medicine from November 2017 to January 2020 were retrospectively analyzed. EGFR gene mutations in NSCLC tissues were detected by amplification refractory mutation system (ARMS)-TaqMan probe method, and clinicopathological data of patients were also collected to analyze the relationship between EGFR gene mutation status and clinicopathological characteristics of patients.Results:EGFR gene mutations were found in 76 of 173 patients, and the total mutation rate was 44.5%. The mutation rate of exon 18 was 6.6% (5/76), all of which were G719X mutation; the mutation rate of exon 19 was 46.1% (35/76), all of which were Del mutation; the mutation rate of exon 20 was 1.3% (1/76), which were EGFR gene 20ins mutation; the mutation rate of exon 21 was 44.7% (34/76), of which 33 cases were EGFR gene L858R mutation, and 1 case was EGFR gene L861Q mutation; 1 case was a double mutation of exon 19 Del combined with exon 20 T790M. The differences in EGFR mutation rates were statistically significant among patients with different gender, smoking history and pathological staging (all P < 0.05), and EGFR mutation rate in female patients was higher than that in male patients [59.7% (46/77) vs. 31.3% (30/96), χ2 = 14.08, P < 0.001], it was lower in patients with smoking history than that in patients without smoking history [27.1% (13/48) vs. 52.9% (63/119), χ2 = 9.22, P < 0.001], and it was higher in patients with adenocarcinoma than that in patients with non-adenocarcinoma [50.7% (75/148) vs. 4.0% (1/25), χ2 = 18.92, P < 0.001]. EGFR mutation status had no relevance with patients' age. Conclusions:The main types of EGFR mutations are exon 19 Del and exon 21 L858R in NSCLC patients in Shiyan, Hubei. EGFR mutations are more likely to occur in adenocarcinoma, female and no-smoking patients.
